



Real-world effectiveness of atezolizumab plus bevacizumab in the patients with hepatocellular carcinoma: a multi-institutional cohort in Taiwan



Yi-Chen Kuo¹, Kai-Cheng Chang^{1,2}, Hui-Yu Chen¹

¹ Department of Pharmacy, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

² School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Science, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Background

- Atezolizumab plus bevacizumab (AtezBeva) treatment was approved for unresectable hepatocellular carcinoma (HCC) patients. Previous evidence demonstrated that the characteristics between real-world and trial patients were different.
- Therefore, this study aimed to evaluate the real-world effectiveness of AtezBeva in unresectable HCC patients.

Method

- Multi-institution electronic medical records (EMR) database in north Taiwan
- Included patients: HCC patients newly initiating AtevBeva during July 2018 to December 2020
- We followed patients from the first date of AtevBeva treatment until disease progressed, death, loss of follow-up, or May 2022.
- Outcome: tumor response according to modified Response Evaluation Criteria in Solid Tumors (mRECIST), progression-free survival (PFS) and overall survival (OS)


Result

Table 1. Baseline Characteristics and Efficacy Outcomes.

Variable	Real-word Group (n=31)	IMBrave Group (n=336)	ASMD*
Mean age (SD) — yr	58 (11.03)	64 (3.75)	0.74
Male sex — %	65	82	0.41
Child-Pugh classification — %			
A	81	100	0.66
A5	65	72	0.10
A6	16	28	0.32
B7	16	0	0.59
B8	3	0	0.24
Barcelona Clinic liver cancer stage — %			
A	7	2	0.20
B	29	15	0.29
C	61	82	0.41
D	3	0	0.24
Presence of macrovascular invasion, extrahepatic spread, or both — %			
Macrovascular invasion	36	38	0.02
Extrahepatic spread	42	63	0.43
Outcomes			P value
Objective response rate — %	25.8	35.4	0.28
Disease control rate — %	64.2	72.6	0.33

*ASMD: absolute standard mean difference; ASMD > 0.2 defined as statistical significance

Figure 1. Kaplan–Meier Analysis of Overall and Progression-free Survival.



Conclusion

The ORR, DCR and OS were similar between clinical trial and real-world. However, the median PFS in real-world patients was relatively better compared with trial patients. We considered the difference may be attribute to better liver cancer stage in real-world patients. The effectiveness of AtevBeva treatment in real-world still need further discussion.